BNC Korea Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on BNC Korea's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 91.5% |
| Return on equity | 12.2% |
| Net Margin | 31.7% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How BNC Korea makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 80,997 | 25,686 | 20,230 | 4,969 |
| 30 Sep 23 | 75,214 | 2,116 | 21,823 | 5,463 |
| 30 Jun 23 | 66,175 | -8,457 | 21,728 | 5,463 |
| 31 Mar 23 | 52,725 | -30,565 | 18,654 | 7,761 |
| 31 Dec 22 | 42,303 | -44,705 | 19,468 | 5,396 |
| 30 Sep 22 | 31,705 | -16,777 | 16,277 | 5,629 |
| 31 Dec 21 | 25,249 | -176,267 | 12,821 | 8,876 |
Quality Earnings: A256840 has a large one-off gain of ₩5.7B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A256840 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A256840 has become profitable over the past 5 years.
Accelerating Growth: A256840 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A256840 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A256840's Return on Equity (12.2%) is considered low.